Sydney, Australia, 31 October 2006: Giaconda (ASX: GIA) today announced that all the motions put to Members were approved at the AGM on a show of hands.
In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, set out below are the proxies received and results in respect of each motion as set out in the Company’s Notice of Annual General Meeting put to the Members at the Annual General Meeting on 30 October 2006.
Re-election of Mr. Richard Woods as a Director
The instructions given to validly appointed proxies in respect of the resolution were as follows:
|
Proxy Directed In Favour
|
Proxy Directed Against
|
Proxy Directed to Abstain
|
Proxy may Exercise Discretion
|
|
1,666,192
|
1,500
|
26,600
|
419,500
|
The motion was carried on a show of hands as an ordinary resolution.
Re-election of Mr. Patrick McLean as a Director
The instructions given to validly appointed proxies in respect of the resolution were as follows:
|
Proxy Directed In Favour
|
Proxy Directed Against
|
Proxy Directed to Abstain
|
Proxy may Exercise Discretion
|
|
1,627,072
|
40,620
|
26,600
|
419,500
|
The motion was carried on a show of hands as an ordinary resolution.
Adoption of the Remuneration Report
The instructions given to validly appointed proxies in respect of the resolution were as follows:
|
Proxy Directed In Favour
|
Proxy Directed Against
|
Proxy Directed to Abstain
|
Proxy may Exercise Discretion
|
|
1,613,072
|
71,220
|
10,000
|
419,500
|
The motion was carried on a show of hands as an ordinary resolution.
Approval of the issue of shares to the Directors with the Company to issue:
283,580 ordinary shares at an issue price of $0.50; and
up to 466,420 at “Market Price” as defined in the Rules for ESP001,
to be acquired by Giaconda ESP001 Pty Limited as trustee for the ESP0001 Employee Share Plan in accordance with the details set out in the information memorandum to the Notice of Meeting.
The instructions given to validly appointed proxies in respect of the resolution were as follows:
|
Proxy Directed In Favour
|
Proxy Directed Against
|
Proxy Directed to Abstain
|
Proxy may Exercise Discretion
|
|
1,410,472
|
209,820
|
74,000
|
419,500
|
The motion was carried on a show of hands as an ordinary resolution.
About Giaconda Limited
Giaconda Limited is a biotechnology company involved in developing and licensing innovative and cost effective medical therapies in the field of gastroenterology. Giaconda’s products are targeted towards the treatment of serious conditions that are not adequately addressed by any existing therapy. In this way, Giaconda’s products are intended to satisfy these significant unmet medical needs of the gastrointestinal market. The Giaconda portfolio consists of five products, all of which are novel combinations of known compounds. Giaconda has two lead products, Myoconda® for the treatment of Crohn’s Disease and Heliconda® for the treatment of resistant Helicobacter pylori infection. Both of these products are ready for Phase III clinical trials, with a Phase IIIa already complete for Myoconda®.
More information is available on the website www.giacondalimited.com
Except for historical information, this news release may contain forward-looking statements that reflect the Company’s current expectation regarding future events. These forward looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.
|
CONTACTS
|
|
|
|
Company
|
|
Media & Investor Relations
|
|
Kirrilli Parker – Chief Administrative Officer
|
|
Fay Weston – Talk Biotech
|
|
T: +61 2 9266 0440
|
|
T: +61 422 206036
|
